CA2337571A1 - Combinaisons d'antihistaminique et d'antagoniste de leucotriene - Google Patents

Combinaisons d'antihistaminique et d'antagoniste de leucotriene Download PDF

Info

Publication number
CA2337571A1
CA2337571A1 CA002337571A CA2337571A CA2337571A1 CA 2337571 A1 CA2337571 A1 CA 2337571A1 CA 002337571 A CA002337571 A CA 002337571A CA 2337571 A CA2337571 A CA 2337571A CA 2337571 A1 CA2337571 A1 CA 2337571A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
antagonist
composition
leukotriene
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002337571A
Other languages
English (en)
Other versions
CA2337571C (fr
Inventor
Hildegard Poppe
Jurgen Engel
Istvan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Priority to CA002337571A priority Critical patent/CA2337571C/fr
Publication of CA2337571A1 publication Critical patent/CA2337571A1/fr
Application granted granted Critical
Publication of CA2337571C publication Critical patent/CA2337571C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002337571A 2001-02-20 2001-02-20 Combinaisons d'antihistaminique et d'antagoniste de leucotriene Expired - Fee Related CA2337571C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002337571A CA2337571C (fr) 2001-02-20 2001-02-20 Combinaisons d'antihistaminique et d'antagoniste de leucotriene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002337571A CA2337571C (fr) 2001-02-20 2001-02-20 Combinaisons d'antihistaminique et d'antagoniste de leucotriene

Publications (2)

Publication Number Publication Date
CA2337571A1 true CA2337571A1 (fr) 2002-08-20
CA2337571C CA2337571C (fr) 2009-12-22

Family

ID=4168402

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002337571A Expired - Fee Related CA2337571C (fr) 2001-02-20 2001-02-20 Combinaisons d'antihistaminique et d'antagoniste de leucotriene

Country Status (1)

Country Link
CA (1) CA2337571C (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087095A2 (fr) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositif osmotique contenant du zafirlukast et un antagoniste h1
WO2005030331A1 (fr) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Traitement antihistaminique combine
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110496124A (zh) * 2019-04-10 2019-11-26 中山大学附属第五医院 治疗脉管畸形的化合物
WO2024126772A1 (fr) 2022-12-15 2024-06-20 Noucor Health, S.A. Composition pharmaceutique comprenant de la rupatadine et du montélukast

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004087095A2 (fr) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Dispositif osmotique contenant du zafirlukast et un antagoniste h1
WO2004087095A3 (fr) * 2003-03-31 2005-07-21 Osmotica Costa Rica Sa Dispositif osmotique contenant du zafirlukast et un antagoniste h1
WO2005030331A1 (fr) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Traitement antihistaminique combine
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype

Also Published As

Publication number Publication date
CA2337571C (fr) 2009-12-22

Similar Documents

Publication Publication Date Title
WO2001060407A3 (fr) Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite
CA2460865A1 (fr) Derives de quinoline utilises comme antagonistes du neuropeptide y
HUP0101158A3 (en) Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus
IL191486A0 (en) Piperidine derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the treatment of tachykinis mediated conditions
WO2002085909A8 (fr) Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
YU58103A (sh) Farmaceutski preparati, dozirane forme i postupci za oralnu primenu epotilona
HUP0103388A2 (hu) Orális, folyékony mukoadhezív készítmények
AU2002360462A8 (en) Compositions containing both sedative and non-sedative antihistamines
TNSN04095A1 (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
WO2003087094A3 (fr) Nouveaux derives du pyrrolidinium
CA2417106A1 (fr) Derives de la piperazine
HUP0204122A2 (hu) Dioxo-tiazolidint és hetformint tartalmazó gyógyszerkészítmény és felhasználása
CA2472954A1 (fr) Aza-arylpiperazines
WO2007067875A3 (fr) Modulateurs de pyridinylsulfonamide de recepteurs de chimiokine
HUP0200284A3 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
WO2002100886A8 (fr) Derives pyrrolidine-2-un comme inhibiteurs de facteur xa
RU2006132043A (ru) Комбинация и фармацевтический препарат для лечения ринита
WO2003087049A3 (fr) Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
WO2006125194A3 (fr) Derives de piperazine et leurs utilisations en tant qu'agents therapeutiques
CA2337571A1 (fr) Combinaisons d'antihistaminique et d'antagoniste de leucotriene
WO2003080125A3 (fr) Medicaments
WO2005053727A3 (fr) Compositions pharmaceutiques pour agents peptidiques bioactifs
WO2002098850A3 (fr) Nouveaux composes et compositions utilises en tant qu'inhibiteurs de cathepsine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180220